“…The disparities in these study results may be attributed to differences in sun exposure or other dietary intake of vitamin D in participants, or differences in the supplement’s stability, because D 2 and D 3 degrade differently with environmental exposures. 70 The Endocrine Society, along with the Canadian Society of Endocrinology and Metabolism and the National Osteoporosis Foundation, published a clinical practice guideline in 2011 titled “Evaluation, Treatment and Prevention of Vitamin D Deficiency.” The Endocrine Society Clinical Guidelines suggests either vitamin D 2 or vitamin D 3 for the treatment and prevention of vitamin D deficiency. 71 The committee also recommended screening of only those individuals who are at high risk for vitamin D deficiency, including patients with osteoporosis, older patients with a history of falls, patients with malabsorption syndrome, chronic renal or hepatic disease, granulomatous diseases (sarcoid), and individuals with darker skin pigmentation (black and Hispanic individuals), obese persons (those with a body mass index [BMI] of >30 kg/m 2 ), and those taking medications known to increase 25(OH)D metabolism, such as anticonvulsants, systemic glucocorticoids, ketoconazole, and HIV medications.…”